Skill
Target prioritization matrix
A general, interview-driven target-discovery workbench: name the biology and the modality you care about, and get back a scored table of candidate targets — druggability, DepMap essentiality, genetic constraint, curated safety, and the real number of drugs already targeting each — assembled from GeneCore intelligence and DrugCore/TrialCore/BiomedCore/PatentCore cross-links.
New to Amass? Connect Amass to Claude first
The prompt
Paste this into Claude
oncology — DepMap-essential druggable protein kinases; modality: small molecule (flag PROTAC); score on essentiality, constraint, safety, competitionUse the Target prioritization matrix skill.
Seed / scope: oncology — DepMap-essential, druggable protein kinases (cell-cycle & mitotic checkpoint)
Modality: small molecule (also flag PROTAC tractability)
Criteria: target class · small-molecule tractability · DepMap essentiality · genetic constraint (LOEUF) ·
curated safety liabilities · competition (# drugs targeting) · clinical/literature/IP activity scan
Stance: show the full field, most-essential first, so I can weigh validation vs therapeutic-window risk
Shortlist size: 12
Output format: markdown table + CSVWhy not just ask the model?
Ask a plain model to "shortlist druggable, essential kinase targets for oncology and score them by essentiality, safety and competition" and it names a handful of famous kinases and invents the numbers — DepMap gene-effect scores, LOEUF values, "drugs in development" counts — that read authoritative and are fabricated.
- Plain model: a few remembered kinases; made-up essentiality, constraint, safety, and competition figures.
- Amass: the real GeneCore records for the live filtered search — every DepMap gene-effect (PLK1 −2.73, WEE1 −2.48, CDK1 −2.34…), every gnomAD LOEUF, every curated safety liability (AURKA: mutagenic / cardiac / neutropenia), and the real
referencesDrugCoreedge count per target (AURKA 19 → WEE1/TTK 2), verbatim from the returned fields.
Why a skill, not a prompt?
Because the value is the interview and the orchestration, not one question. The skill asks modality first, then which criteria to score, then the output format — and turns those answers into GeneCore enum filters (targetClass=ENZYME, isEssential=true, isDruggable=true, tractabilityModality). It unions two query angles to break the 10-result cap (10 + 10, overlap 4 → 16 unique), reads the target-intelligence fields straight from the search response, then fans out one get_amass_genecore_record per candidate for the referencesDrugCore competition edge and one TrialCore / BiomedCore / PatentCore search each for the activity scan. Then — because it is a general workbench — it offers to freeze this exact configuration into a dedicated, one-line reusable skill, so the workbench spawns the narrow, repeatable tool.
Honest scope
Candidates are a union of relevance-ranked top-10 GeneCore searches — a broadened sample, not a census. Target-intelligence fields are verbatim from Open Targets / gnomAD / DepMap as harmonized in GeneCore; null = "no data recorded," not zero. drugs_targeting is the length of each gene's referencesDrugCore edge — 0 would mean unprecedented, not undruggable. The TrialCore / BiomedCore / PatentCore columns are capped ≤10 samples: on this mature class all 12 kinases saturate at 10+, so those columns don't differentiate — the discriminating competition signal is the DrugCore edge, and the skill says so rather than presenting three dead columns as a ranking. And DepMap essentiality is double-edged — a pan-essential kinase is a strong dependency and a narrow-therapeutic-window risk.
Install the skill
Add the skill to Claude
Install every Amass skill with one command — npx skills add amass-technologies/public-skills — or download the SKILL.md from GitHub and add it to Claude (Settings → Capabilities → Skills, or drop it in your Claude Code skills directory). Then paste the prompt above to trigger it.
More from the library
Keep exploring
One-line read: approved, but already evolving. KRAS G12C went from "undruggable" to two approved drugs, and the field has immediately pivoted to a sec…
Biomedical Evidence Scout
Name a drug, target, mechanism, or indication; get a landscape briefing that maps the published literature AND the clinical pipeline together — every paper and trial carrying a real Amass ID, PMID, or NCT you can check.
| rank | title | journal | publicationDate |
|---|---|---|---|
| 1 | Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico | The New England journal of medicine | 2022-02-10 |
| 2 | Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial | JAMA network open | 2023-04-03 |
| 3 | Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 Trial | medRxiv (preprint) | 2022-09-21 |
Trial evidence trace
Paste one clinical-trial ID; get the exact published papers that describe it — pulled from Amass's publication↔trial graph, with trust metadata and abstract-grounded relevance notes.
1. Pivotal Phase-3 program
AMASS EVIDENCE BRIEF
Tirzepatide evidence brief
Name a drug asset; get a citation-auditable Word evidence brief — pivotal Phase-3 trials, grounded efficacy and safety findings, and the trial↔paper links — every figure verbatim from Amass.
Run it yourself
Connect Amass to Claude and paste the prompt.
No build, no deploy — the connector takes about a minute, then this workflow runs on your own inputs.